AR085736A1 - Compuestos de complejos de fe(iii) para el tratamiento y profilaxis de sintomas de deficiencia de hierro y anemias por deficiencia de hierro - Google Patents

Compuestos de complejos de fe(iii) para el tratamiento y profilaxis de sintomas de deficiencia de hierro y anemias por deficiencia de hierro

Info

Publication number
AR085736A1
AR085736A1 ARP120101058A ARP120101058A AR085736A1 AR 085736 A1 AR085736 A1 AR 085736A1 AR P120101058 A ARP120101058 A AR P120101058A AR P120101058 A ARP120101058 A AR P120101058A AR 085736 A1 AR085736 A1 AR 085736A1
Authority
AR
Argentina
Prior art keywords
iron deficiency
iii
compounds
complexes
treatment
Prior art date
Application number
ARP120101058A
Other languages
English (en)
Inventor
Otto Dr Geisser Peter
Dr Reim Stefan
Dr Sieber Diana
Dr Mayer Simona
Dr Philipp Erik
Dr Schmitt Jrg
Dr Schwarz Katrin
Dr Kalogerakis Aris
Dr Bark Thomas
Dr Buhr Wilm
Dr Burckhardt Susanna
Dr Burgert Michael
Canclini Camillo
Dr Drrenberger Franz
Dr Funk Felix
Original Assignee
Vifor Int Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44140927&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR085736(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Vifor Int Ag filed Critical Vifor Int Ag
Publication of AR085736A1 publication Critical patent/AR085736A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
    • C07F15/02—Iron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/295—Iron group metal compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/80—Oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente se refiere a compuestos de complejos de hierro(III) y composiciones farmacéuticas que comprenden los mismos para su uso como medicamentos, en particular para el tratamiento y/o profilaxis de síntomas de deficiencia de hierro y anemias por deficiencia de hierro. Reivindicación 1: Compuestos de complejos de hierro(III) pirimidin-2-ol-1-óxido o sales farmacéuticamente aceptables de los mismos para su uso como medicamentos.
ARP120101058A 2011-03-29 2012-03-28 Compuestos de complejos de fe(iii) para el tratamiento y profilaxis de sintomas de deficiencia de hierro y anemias por deficiencia de hierro AR085736A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP11160151 2011-03-29

Publications (1)

Publication Number Publication Date
AR085736A1 true AR085736A1 (es) 2013-10-23

Family

ID=44140927

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP120101058A AR085736A1 (es) 2011-03-29 2012-03-28 Compuestos de complejos de fe(iii) para el tratamiento y profilaxis de sintomas de deficiencia de hierro y anemias por deficiencia de hierro

Country Status (31)

Country Link
US (1) US9422247B2 (es)
EP (1) EP2691376B1 (es)
JP (1) JP5923161B2 (es)
KR (1) KR101889050B1 (es)
CN (1) CN103429575B (es)
AR (1) AR085736A1 (es)
AU (1) AU2012234292B2 (es)
BR (1) BR112013024722B1 (es)
CA (1) CA2829240C (es)
CL (1) CL2013002766A1 (es)
CO (1) CO6811850A2 (es)
CR (1) CR20130485A (es)
DK (1) DK2691376T3 (es)
DO (1) DOP2013000213A (es)
EA (1) EA026192B1 (es)
EC (1) ECSP13012904A (es)
ES (1) ES2560964T3 (es)
GT (1) GT201300224A (es)
HU (1) HUE026712T2 (es)
IL (1) IL228502A (es)
MA (1) MA34977B1 (es)
MX (1) MX358194B (es)
MY (1) MY168952A (es)
PE (1) PE20141319A1 (es)
PL (1) PL2691376T3 (es)
PT (1) PT2691376E (es)
SG (1) SG193981A1 (es)
TN (1) TN2013000379A1 (es)
TW (1) TWI510496B (es)
WO (1) WO2012130882A1 (es)
ZA (1) ZA201308050B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2015007974A (es) 2012-12-21 2016-03-09 Vifor Int Ag Compuestos de complejos de fe (iii) para el tratamiento y la profilaxis de los sintomas de la deficiencia de hierro y las anemias por deficiencia de hierro.
CN103951552B (zh) * 2014-04-11 2015-09-30 浙江宏元药业有限公司 瑞舒伐他汀中间体及其制备方法
RU2625739C1 (ru) * 2016-09-28 2017-07-18 Общество с ограниченной ответственностью Научно-производственное предприятие "Эксорб" Фармакологическая композиция на основе соединений железа

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US474670A (en) 1892-05-10 Automatic fire-alarm
GB842637A (en) 1955-12-27 1960-07-27 Andre Georges Jules Jallais Glass frames, more especially for forced cultivation
EP0107458B1 (en) 1982-10-22 1987-07-29 National Research Development Corporation Pharmaceutical compositions
GB8325496D0 (en) * 1983-09-23 1983-10-26 Hider R C Pharmaceutical compositions
US4788281A (en) 1984-01-04 1988-11-29 Tosoni Anthony L Dextran hexonic acid derivative, ferric hydroxide complex and method manufacture thereof
GB8410289D0 (en) 1984-04-19 1984-05-31 Callingham B A Pharmaceutical compositions
IT1222654B (it) 1987-09-14 1990-09-12 Schering Ag Complesso micellare di ferro-citrato
JPH0283400A (ja) 1988-09-21 1990-03-23 Snow Brand Milk Prod Co Ltd 鉄カゼインの製造方法
ES2044777B1 (es) 1992-03-03 1994-08-01 Dabeer Sa Procedimiento de obtencion de un quelato de hierro de gran solubilidad.
US20030236224A1 (en) 1997-12-09 2003-12-25 Hedlund Bo E. Modified polysaccharides exhibiting altered biological recognition
IT1297022B1 (it) 1997-12-24 1999-08-03 Chemi Spa Complesso di ferro-succinilcaseina, processo per la sua preparazione e composizioni farmaceutiche che lo contengono
DE10253843B3 (de) 2002-11-14 2004-05-06 Bizerba Gmbh & Co. Kg Etikettiervorrichtung für bewegte Gegenstände und Verfahren zur Etikettierung von bewegten Gegenständen
JP4931352B2 (ja) 2004-01-14 2012-05-16 月桂冠株式会社 鉄補給剤及びその利用
BRPI0515847A (pt) 2004-10-08 2008-08-12 Unilever Nv uso de um complexo de ferro, composição alimentìcia, gênero alimentìcio fortificado com ferro, composição de bebida, bebida fortificada com ferro, suplemento alimentar e composição farmacêutica
US20090035385A1 (en) 2004-12-22 2009-02-05 Drugtech Corporation Compositions including iron
CN100443485C (zh) 2005-04-08 2008-12-17 吴华君 叶绿酸合铁钠盐衍生物、制备方法及用途
JP4948056B2 (ja) 2005-09-02 2012-06-06 月桂冠株式会社 疲労の予防又は改善剤
WO2007062546A1 (fr) 2005-11-30 2007-06-07 Chongqing Pharmaceutical Research Institute Co., Ltd. Complexes fer-saccharide faciles a reconstituer et leur procede de fabrication
FR2916592B1 (fr) 2007-05-25 2017-04-14 Groupe Des Ecoles De Telecommunications(Get)-Ecole Nat Superieure Des Telecommunications(Enst) Procede de securisation d'echange d'information,dispositif, et produit programme d'ordinateur correspondant
CN101481404B (zh) 2008-12-17 2011-10-05 中国农业大学 一种酶解乳蛋白亚铁络合物微胶囊补铁剂及其制备方法

Also Published As

Publication number Publication date
TWI510496B (zh) 2015-12-01
MA34977B1 (fr) 2014-03-01
EA201301083A1 (ru) 2014-03-31
CA2829240C (en) 2016-11-22
PE20141319A1 (es) 2014-10-29
MX358194B (es) 2018-07-16
SG193981A1 (en) 2013-11-29
TW201245212A (en) 2012-11-16
KR20140027196A (ko) 2014-03-06
CL2013002766A1 (es) 2014-03-21
CA2829240A1 (en) 2012-10-04
CR20130485A (es) 2014-05-20
TN2013000379A1 (en) 2015-01-20
BR112013024722A2 (pt) 2016-12-20
AU2012234292A1 (en) 2013-10-17
CO6811850A2 (es) 2013-12-16
US9422247B2 (en) 2016-08-23
DK2691376T3 (en) 2016-02-15
BR112013024722B1 (pt) 2022-04-12
JP5923161B2 (ja) 2016-05-24
AU2012234292B2 (en) 2016-09-22
PL2691376T3 (pl) 2016-06-30
EA026192B1 (ru) 2017-03-31
US20140162994A1 (en) 2014-06-12
EP2691376A1 (de) 2014-02-05
ES2560964T3 (es) 2016-02-23
ECSP13012904A (es) 2013-12-31
IL228502A (en) 2015-02-26
HUE026712T2 (en) 2016-07-28
IL228502A0 (en) 2013-12-31
ZA201308050B (en) 2016-01-27
MY168952A (en) 2019-01-28
WO2012130882A1 (de) 2012-10-04
KR101889050B1 (ko) 2018-08-20
PT2691376E (pt) 2016-03-02
JP2014509624A (ja) 2014-04-21
MX2013010964A (es) 2013-10-17
NZ616045A (en) 2015-04-24
EP2691376B1 (de) 2015-12-09
CN103429575B (zh) 2016-08-31
CN103429575A (zh) 2013-12-04
DOP2013000213A (es) 2013-11-15
GT201300224A (es) 2015-01-20

Similar Documents

Publication Publication Date Title
CR20150629A (es) Compuestos químicos
ECSP12012318A (es) Inhibidores de pirazolil quinazolina cinasa
CL2012000589A1 (es) Compuestos derivados de pirrolo piridin carboxamidas, inhibidores de jak2; composición farmacéutica que los comprende; uso en el tratamiento de enfermedades mieloproliferativas o cáncer, tales como policitemia vera, trombocitopenia esencial, mieloma múltiple, entre otras.
CR20150326A (es) Inhibidores de autotaxina
CR20120478A (es) COMPUESTOS DEL COMPLEJO DE Fe(III) PARA EL TRATAMIENTO Y PROFILAXIS DE LOS SÍNTOMAS DE DEFICIENCIA DE HIERRO Y LAS ANEMIAS POR DEFICIENCIA DE HIERRO
UY35916A (es) Compuestos tricíclicos como agentes antineoplásicos inhibidores del bromodominio
MX2015008627A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
BR112013023876A2 (pt) derivados de pirroltriazinona como inibidores de pi3k
DOP2014000043A (es) Pirimidinas anilladas sustituidas y uso de las mismas
CU20140068A7 (es) Triazolopiridinas sustituidas
CU20120161A7 (es) 5-fluoro-1h-pirazolopiridinas sustituidas
NI201500096A (es) Compuesto químicos
BR112013029256A8 (pt) combinação farmacêutica para uso no tratamento de pacientes com diabetes tipo 2
BR112014005025A2 (pt) composição farmacêutica para uso no tratamento de uma doença neurodegenerativa
UY36875A (es) Composiciones inhibidoras de bromodominios para el tratamiento de diversas enfermedades
UY31922A (es) Compuestos
UY35276A (es) Nuevos compuestos que inhiben la actividad de Lp-PLA2
CL2015000039A1 (es) Derivados estra-1,3,5(10),16-tetraeno-3-sustituidos, preparaciones farmacéuticas que los comprenden y su uso en la preparación de medicamentos para tratar la endometriosis.
BR112015003957A2 (pt) alfa-1-microglobulina para uso no tratamento de doenças relacionadas com a mitocôndria
MX2016000294A (es) Composicion farmaceutica para liberacion sostenida de lanreotida.
CO6382113A2 (es) Compuestos quimicos
AR085736A1 (es) Compuestos de complejos de fe(iii) para el tratamiento y profilaxis de sintomas de deficiencia de hierro y anemias por deficiencia de hierro
BR112014009760A2 (pt) análogos de ácido siálico, seu uso e composição farmacêutica e composição farmacêutica de liberação sustentada os compreendendo
AR086606A1 (es) Compuestos del complejo de fe(iii) para el tratamiento y profilaxis de los sintomas de la deficiencia de hierro y las anemias por deficiencia de hierro
BR112015004115A2 (pt) composições farmacêuticas compreendendo flurbiprofeno

Legal Events

Date Code Title Description
FB Suspension of granting procedure